Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Tournigand

Showing results (11-20 of 47) with videos related to

Pageof 5
Sort By:
Cancer|June 8, 2001
Correlation between progression free survival and response rate in patients with metastatic colorectal carcinomaC Louvet, A de Gramont, C Tournigand, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 21, 2016
Use of chemotherapy near the end of life: what factors matter?P Rochigneux, J L Raoul, Y Beaussant, et al.
The British Journal of Dermatology|April 3, 2016
End-of-life care for hospitalized patients with metastatic melanoma in France: a nationwide, register-based studyI Gallais Sérézal, Y Beaussant, P Rochigneux, et al.
La Revue De Medecine Interne|April 8, 2011
[Nasal septum perforation and bevacizumab]L Bengrine-Lefevre, P Afchain, B Chibaudel, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|March 30, 2018
Bevacizumab improves survival in patients with synchronous colorectal liver metastases provided the primary tumor is resected firstC Lim, A Doussot, M Osseis, et al.
La Revue De Medecine Interne|January 1, 1997
[Modulation of 5-fluorouracil with folinic acid in advanced colorectal cancers. Groupe d'étude et de recherche sur les cancers de l'ovaire et digestifs (GERCOD)]A de Gramont, C Louvet, T André, et al.
Oncogene|March 14, 2000
Differential roles of JNK and Smad2 signaling pathways in the inhibition of c-Myc-induced cell death by TGF-betaA Mazars, C Tournigand, P Mollat, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 28, 2004
Oxaliplatin reintroduction in patients previously treated with leucovorin, fluorouracil and oxaliplatin for metastatic colorectal cancerF Maindrault-Goebel, C Tournigand, T André, et al.
Anti-Cancer Drugs|October 19, 2000
Synergistic antitumoral activity of combined UFT, folinic acid and oxaliplatin against human colorectal HT29 cell xenografts in athymic nude miceC Louvet, A M Coudray, C Tournigand, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 6, 2009
Incidence and evolution of oxaliplatin-induced peripheral sensory neuropathy in diabetic patients with colorectal cancer: a pooled analysis of three phase III studiesR K Ramanathan, M L Rothenberg, A de Gramont, et al.
Pageof 5

Showing results (11-20 of 47) with videos related to

Sort By:
Pageof 5
Cancer|June 8, 2001
Correlation between progression free survival and response rate in patients with metastatic colorectal carcinomaC Louvet, A de Gramont, C Tournigand, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 21, 2016
Use of chemotherapy near the end of life: what factors matter?P Rochigneux, J L Raoul, Y Beaussant, et al.
The British Journal of Dermatology|April 3, 2016
End-of-life care for hospitalized patients with metastatic melanoma in France: a nationwide, register-based studyI Gallais Sérézal, Y Beaussant, P Rochigneux, et al.
La Revue De Medecine Interne|April 8, 2011
[Nasal septum perforation and bevacizumab]L Bengrine-Lefevre, P Afchain, B Chibaudel, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|March 30, 2018
Bevacizumab improves survival in patients with synchronous colorectal liver metastases provided the primary tumor is resected firstC Lim, A Doussot, M Osseis, et al.
La Revue De Medecine Interne|January 1, 1997
[Modulation of 5-fluorouracil with folinic acid in advanced colorectal cancers. Groupe d'étude et de recherche sur les cancers de l'ovaire et digestifs (GERCOD)]A de Gramont, C Louvet, T André, et al.
Oncogene|March 14, 2000
Differential roles of JNK and Smad2 signaling pathways in the inhibition of c-Myc-induced cell death by TGF-betaA Mazars, C Tournigand, P Mollat, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 28, 2004
Oxaliplatin reintroduction in patients previously treated with leucovorin, fluorouracil and oxaliplatin for metastatic colorectal cancerF Maindrault-Goebel, C Tournigand, T André, et al.
Anti-Cancer Drugs|October 19, 2000
Synergistic antitumoral activity of combined UFT, folinic acid and oxaliplatin against human colorectal HT29 cell xenografts in athymic nude miceC Louvet, A M Coudray, C Tournigand, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 6, 2009
Incidence and evolution of oxaliplatin-induced peripheral sensory neuropathy in diabetic patients with colorectal cancer: a pooled analysis of three phase III studiesR K Ramanathan, M L Rothenberg, A de Gramont, et al.
Pageof 5